Back to search results

Observational Study on Precision Medicine for Advanced Cancer

This observational study, called ELIA, is looking at how well advanced cancer patients in community clinics receive precision medicine care. Precision medicine uses detailed genetic testing of your tumor to find the best treatment for you. The study aims to understand and reduce "leakage," which means when testing or treatment based on genetic results doesn't happen as it should. Researchers are comparing patients who receive comprehensive genomic profiling (TSO500 testing, ELIA software, and molecular pathologist consultations) with those who receive limited or no genetic testing. The goal is to see if eligible patients get the correct genetic test-informed treatment and how quickly these services are provided. You might be able to join if you are an adult with newly diagnosed or changing advanced cancer (like recurrent, metastatic, or high-grade solid tumors or myeloid malignancies) and genomic testing is recommended for you. This study is currently unclear on its recruitment status.

Study design
This is an observational study, meaning researchers will watch and collect information without assigning specific treatments. It plans to include 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06090513

Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients

Not Yet Recruiting
Not specifiedAges 18+Observational
Bien-Willner Physicians Group PA
~300 participants
Updated 2024-08-06 on ClinicalTrials.gov
What's tested:Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultationlimited genetic testing or no testing

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of eligible patients getting the correct genetic test-informed treatment
Measured over 2 years
+1 more outcome measured

Conditions

Advanced Cancer
Solid Tumor, Adult
Myeloid Malignancy

Explore related trials

Myeloid NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Gabriel A Bien-Willner, MD, PhD · PRINCIPAL_INVESTIGATOR · Bien-Willner Physicians Grp PA

Who to contact

Haydee Diaz, MBASCP
[email protected]
3468310189
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

newly diagnosed or change in status Advanced Cancer patient (recurrent, refractory, metastatic, or high grade)
Cancer patient for whom genomic testing (comprehensive genomic profile (CGP)) is recommended by relevant guidelines

Exclusion

Patient does not seek additional treatment
Patient younger than 18 years
Treatment provided at a tertiary medical center
CGP testing already performed and there is no change in patient cancer status

What this trial measures

  • Percentage of eligible patients getting the correct genetic test-informed treatment2 years

    Demonstration that deployment of SOC services and ELIA improves % of eligible patients placed on appropriate targeted therapies according to guidelines

  • Service turn-around-time2 years

    Demonstration that standard-of-care services and ELIA improves turnaround times for getting actionable results, allowing physicians to make timely decisions.